Vulvovaginal rhabdomyosarcoma

Vulvovaginal rhabdomyosarcoma is a rare malignant soft tissue tumor arising from embryonal skeletal muscle precursor cells in the vulva or vagina. It is the most common soft tissue sarcoma of the female genital tract in children, predominantly affecting infants and young girls, though it can occasionally occur in adolescents and adults. The embryonal subtype, particularly the botryoid variant (sarcoma botryoides), is the most frequently encountered form, characterized by grape-like polypoid masses that protrude from the vaginal opening. Patients typically present with vaginal bleeding, a visible or palpable mass at the vaginal introitus or vulva, and occasionally vaginal discharge or urinary symptoms due to local mass effect. The tumor arises from the mesenchymal tissues of the lower female genital tract and can invade locally into surrounding pelvic structures if left untreated. Diagnosis is established through biopsy and histopathological examination, which reveals characteristic rhabdomyoblasts with immunohistochemical positivity for skeletal muscle markers such as desmin and myogenin. Staging involves imaging studies including MRI of the pelvis and CT scans to assess for metastatic disease. Treatment has evolved significantly over recent decades through cooperative group trials, particularly those conducted by the Intergroup Rhabdomyosarcoma Study (IRS) and the Children's Oncology Group (COG). Current management typically involves a multimodal approach combining chemotherapy (usually vincristine, actinomycin D, and cyclophosphamide — the VAC regimen) with conservative surgical resection. The emphasis has shifted away from radical surgery such as pelvic exenteration toward organ-preserving approaches, with chemotherapy often used as the primary treatment to shrink the tumor before limited surgical excision. Radiation therapy may be employed in select cases but is generally avoided in young children when possible due to long-term side effects. Prognosis is generally favorable, particularly for the botryoid variant in young children, with reported survival rates exceeding 90% in localized disease when treated with contemporary protocols.

Common questions about Vulvovaginal rhabdomyosarcoma